Evaluation of different protocols for gene transfer into non-obese diabetes/severe combined immunodeficiency disease mouse repopulating cells

Peter Ebeling, P. Bach, U. Sorg, A. Schneider, T. Trarbach, D. Dilloo, H. Hanenberg, S. Niesert, S. Seeber, T. Moritz, M. Flasshove

Research output: Contribution to journalArticle

Abstract

Purpose: Although gene transfer with retroviral vectors has shown distinct clinical success in defined settings, efficient genetic manipulation of hematopoietic progenitor cells remains a challenge. To address this issue we have evaluated different transduction protocols and retroviral constructs in the non-obese diabetes (NOD)/severe combined immunodeficiency disease (SCID) xenograft model. Methods: An extended transduction protocol requiring 144 h of in vitro manipulation was compared to a more conventional protocol requiring 96 h only. Result: While pretransplantation analysis of cells transduced with a retroviral vector, expressing the enhanced green fluorescent protein (EGFP) marker gene, demonstrated significantly higher overall transduction rates for the extended protocol (33.6 ± 2.3 vs. 22.1 ± 3.8%), EGFP expression in CD34+ cells before transplantation (4.0 ± 0.9 vs. 11.6 ± 2.5%), engraftment of human cells in NOD/SCID bone marrow 4 weeks after transplantation (4.5 ± 1.7 vs. 36.5 ± 9.4%) and EGFP expression in these cells (0 ± 0 vs. 11.3 ± 2.8%) were significantly impaired. When the 96 h protocol was used in combination with the spleen focus forming virus (SFFV)/murine embryonic stem cell (MESV) hybrid vector SFβ11-EGFP, high transduction rates for CD45+ (41.0 ± 5.3%) and CD34+ (38.5 ± 3.7%) cells prior to transplantation, as well as efficient human cell engraftment in NOD/SCID mice 4 weeks after transplantation (32.4 ± 3.5%), was detected. Transgene expression was observed in B-lymphoid (15.9 ± 2.0%), myeloid (36.5 ± 3.5%) and CD34+ cells (10.1 ± 1.5%). Conclusion: Our data show that CD34+ cells maintained in cytokines for multiple days may differentiate and loose their capacity to contribute to the haematological reconstitution of NOD/SCID mice. In addition, the SFFV/MESV hybrid vector SFβ11-EGFP allows efficient transduction of and gene expression in haematopoietic progenitor cells.

Original languageEnglish (US)
Pages (from-to)199-209
Number of pages11
JournalJournal of Cancer Research and Clinical Oncology
Volume133
Issue number3
DOIs
StatePublished - Mar 2007
Externally publishedYes

Fingerprint

Severe Combined Immunodeficiency
Spleen Focus-Forming Viruses
Genes
Transplantation
Hematopoietic Stem Cells
Bone Marrow Diseases
Cell Transplantation
Embryonic Stem Cells
Transgenes
Heterografts
enhanced green fluorescent protein
Cytokines
Gene Expression

Keywords

  • Gene therapy
  • Hematopoietic stem cells
  • NOD/SCID mouse
  • Retrovirus

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Evaluation of different protocols for gene transfer into non-obese diabetes/severe combined immunodeficiency disease mouse repopulating cells. / Ebeling, Peter; Bach, P.; Sorg, U.; Schneider, A.; Trarbach, T.; Dilloo, D.; Hanenberg, H.; Niesert, S.; Seeber, S.; Moritz, T.; Flasshove, M.

In: Journal of Cancer Research and Clinical Oncology, Vol. 133, No. 3, 03.2007, p. 199-209.

Research output: Contribution to journalArticle

Ebeling, P, Bach, P, Sorg, U, Schneider, A, Trarbach, T, Dilloo, D, Hanenberg, H, Niesert, S, Seeber, S, Moritz, T & Flasshove, M 2007, 'Evaluation of different protocols for gene transfer into non-obese diabetes/severe combined immunodeficiency disease mouse repopulating cells', Journal of Cancer Research and Clinical Oncology, vol. 133, no. 3, pp. 199-209. https://doi.org/10.1007/s00432-006-0158-9
Ebeling, Peter ; Bach, P. ; Sorg, U. ; Schneider, A. ; Trarbach, T. ; Dilloo, D. ; Hanenberg, H. ; Niesert, S. ; Seeber, S. ; Moritz, T. ; Flasshove, M. / Evaluation of different protocols for gene transfer into non-obese diabetes/severe combined immunodeficiency disease mouse repopulating cells. In: Journal of Cancer Research and Clinical Oncology. 2007 ; Vol. 133, No. 3. pp. 199-209.
@article{70d9c397926448eea6b3601318b94e23,
title = "Evaluation of different protocols for gene transfer into non-obese diabetes/severe combined immunodeficiency disease mouse repopulating cells",
abstract = "Purpose: Although gene transfer with retroviral vectors has shown distinct clinical success in defined settings, efficient genetic manipulation of hematopoietic progenitor cells remains a challenge. To address this issue we have evaluated different transduction protocols and retroviral constructs in the non-obese diabetes (NOD)/severe combined immunodeficiency disease (SCID) xenograft model. Methods: An extended transduction protocol requiring 144 h of in vitro manipulation was compared to a more conventional protocol requiring 96 h only. Result: While pretransplantation analysis of cells transduced with a retroviral vector, expressing the enhanced green fluorescent protein (EGFP) marker gene, demonstrated significantly higher overall transduction rates for the extended protocol (33.6 ± 2.3 vs. 22.1 ± 3.8{\%}), EGFP expression in CD34+ cells before transplantation (4.0 ± 0.9 vs. 11.6 ± 2.5{\%}), engraftment of human cells in NOD/SCID bone marrow 4 weeks after transplantation (4.5 ± 1.7 vs. 36.5 ± 9.4{\%}) and EGFP expression in these cells (0 ± 0 vs. 11.3 ± 2.8{\%}) were significantly impaired. When the 96 h protocol was used in combination with the spleen focus forming virus (SFFV)/murine embryonic stem cell (MESV) hybrid vector SFβ11-EGFP, high transduction rates for CD45+ (41.0 ± 5.3{\%}) and CD34+ (38.5 ± 3.7{\%}) cells prior to transplantation, as well as efficient human cell engraftment in NOD/SCID mice 4 weeks after transplantation (32.4 ± 3.5{\%}), was detected. Transgene expression was observed in B-lymphoid (15.9 ± 2.0{\%}), myeloid (36.5 ± 3.5{\%}) and CD34+ cells (10.1 ± 1.5{\%}). Conclusion: Our data show that CD34+ cells maintained in cytokines for multiple days may differentiate and loose their capacity to contribute to the haematological reconstitution of NOD/SCID mice. In addition, the SFFV/MESV hybrid vector SFβ11-EGFP allows efficient transduction of and gene expression in haematopoietic progenitor cells.",
keywords = "Gene therapy, Hematopoietic stem cells, NOD/SCID mouse, Retrovirus",
author = "Peter Ebeling and P. Bach and U. Sorg and A. Schneider and T. Trarbach and D. Dilloo and H. Hanenberg and S. Niesert and S. Seeber and T. Moritz and M. Flasshove",
year = "2007",
month = "3",
doi = "10.1007/s00432-006-0158-9",
language = "English (US)",
volume = "133",
pages = "199--209",
journal = "Journal of Cancer Research and Clinical Oncology",
issn = "0171-5216",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Evaluation of different protocols for gene transfer into non-obese diabetes/severe combined immunodeficiency disease mouse repopulating cells

AU - Ebeling, Peter

AU - Bach, P.

AU - Sorg, U.

AU - Schneider, A.

AU - Trarbach, T.

AU - Dilloo, D.

AU - Hanenberg, H.

AU - Niesert, S.

AU - Seeber, S.

AU - Moritz, T.

AU - Flasshove, M.

PY - 2007/3

Y1 - 2007/3

N2 - Purpose: Although gene transfer with retroviral vectors has shown distinct clinical success in defined settings, efficient genetic manipulation of hematopoietic progenitor cells remains a challenge. To address this issue we have evaluated different transduction protocols and retroviral constructs in the non-obese diabetes (NOD)/severe combined immunodeficiency disease (SCID) xenograft model. Methods: An extended transduction protocol requiring 144 h of in vitro manipulation was compared to a more conventional protocol requiring 96 h only. Result: While pretransplantation analysis of cells transduced with a retroviral vector, expressing the enhanced green fluorescent protein (EGFP) marker gene, demonstrated significantly higher overall transduction rates for the extended protocol (33.6 ± 2.3 vs. 22.1 ± 3.8%), EGFP expression in CD34+ cells before transplantation (4.0 ± 0.9 vs. 11.6 ± 2.5%), engraftment of human cells in NOD/SCID bone marrow 4 weeks after transplantation (4.5 ± 1.7 vs. 36.5 ± 9.4%) and EGFP expression in these cells (0 ± 0 vs. 11.3 ± 2.8%) were significantly impaired. When the 96 h protocol was used in combination with the spleen focus forming virus (SFFV)/murine embryonic stem cell (MESV) hybrid vector SFβ11-EGFP, high transduction rates for CD45+ (41.0 ± 5.3%) and CD34+ (38.5 ± 3.7%) cells prior to transplantation, as well as efficient human cell engraftment in NOD/SCID mice 4 weeks after transplantation (32.4 ± 3.5%), was detected. Transgene expression was observed in B-lymphoid (15.9 ± 2.0%), myeloid (36.5 ± 3.5%) and CD34+ cells (10.1 ± 1.5%). Conclusion: Our data show that CD34+ cells maintained in cytokines for multiple days may differentiate and loose their capacity to contribute to the haematological reconstitution of NOD/SCID mice. In addition, the SFFV/MESV hybrid vector SFβ11-EGFP allows efficient transduction of and gene expression in haematopoietic progenitor cells.

AB - Purpose: Although gene transfer with retroviral vectors has shown distinct clinical success in defined settings, efficient genetic manipulation of hematopoietic progenitor cells remains a challenge. To address this issue we have evaluated different transduction protocols and retroviral constructs in the non-obese diabetes (NOD)/severe combined immunodeficiency disease (SCID) xenograft model. Methods: An extended transduction protocol requiring 144 h of in vitro manipulation was compared to a more conventional protocol requiring 96 h only. Result: While pretransplantation analysis of cells transduced with a retroviral vector, expressing the enhanced green fluorescent protein (EGFP) marker gene, demonstrated significantly higher overall transduction rates for the extended protocol (33.6 ± 2.3 vs. 22.1 ± 3.8%), EGFP expression in CD34+ cells before transplantation (4.0 ± 0.9 vs. 11.6 ± 2.5%), engraftment of human cells in NOD/SCID bone marrow 4 weeks after transplantation (4.5 ± 1.7 vs. 36.5 ± 9.4%) and EGFP expression in these cells (0 ± 0 vs. 11.3 ± 2.8%) were significantly impaired. When the 96 h protocol was used in combination with the spleen focus forming virus (SFFV)/murine embryonic stem cell (MESV) hybrid vector SFβ11-EGFP, high transduction rates for CD45+ (41.0 ± 5.3%) and CD34+ (38.5 ± 3.7%) cells prior to transplantation, as well as efficient human cell engraftment in NOD/SCID mice 4 weeks after transplantation (32.4 ± 3.5%), was detected. Transgene expression was observed in B-lymphoid (15.9 ± 2.0%), myeloid (36.5 ± 3.5%) and CD34+ cells (10.1 ± 1.5%). Conclusion: Our data show that CD34+ cells maintained in cytokines for multiple days may differentiate and loose their capacity to contribute to the haematological reconstitution of NOD/SCID mice. In addition, the SFFV/MESV hybrid vector SFβ11-EGFP allows efficient transduction of and gene expression in haematopoietic progenitor cells.

KW - Gene therapy

KW - Hematopoietic stem cells

KW - NOD/SCID mouse

KW - Retrovirus

UR - http://www.scopus.com/inward/record.url?scp=33846447419&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846447419&partnerID=8YFLogxK

U2 - 10.1007/s00432-006-0158-9

DO - 10.1007/s00432-006-0158-9

M3 - Article

VL - 133

SP - 199

EP - 209

JO - Journal of Cancer Research and Clinical Oncology

JF - Journal of Cancer Research and Clinical Oncology

SN - 0171-5216

IS - 3

ER -